.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Daiichi Sankyo
Moodys
Merck
Harvard Business School
Novartis
Cerilliant
Fish and Richardson
Teva
Colorcon

Generated: July 21, 2017

DrugPatentWatch Database Preview

TARKA Drug Profile

« Back to Dashboard

What is the patent landscape for Tarka, and when can generic versions of Tarka launch?

Tarka is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TARKA is trandolapril; verapamil hydrochloride. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the trandolapril; verapamil hydrochloride profile page.

Summary for Tradename: TARKA

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list41
Clinical Trials: see list4
Patent Applications: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TARKA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-003Oct 22, 1996ABRXYesNo► Subscribe► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-002Oct 22, 1996ABRXYesYes► Subscribe► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-001Oct 22, 1996ABRXYesNo► Subscribe► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-004Oct 22, 1996ABRXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TARKA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-004Oct 22, 19964,933,361► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-004Oct 22, 19965,721,244► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-003Oct 22, 19964,933,361► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-002Oct 22, 19964,933,361► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-001Oct 22, 19964,933,361► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TARKA

Drugname Dosage Strength RLD Submissiondate
trandolapril and verapamil hydrochlorideExtended-release Tablets1 mg/240 mgTarka2/20/2008
trandolapril and verapamil hydrochlorideExtended-release Tablets2 mg/180 mg and 2 mg/240 mgTarka11/9/2007
trandolapril and verapamil hydrochlorideExtended-release Tablets4 mg/ 240 mgTarka7/24/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
AstraZeneca
Mallinckrodt
Novartis
Accenture
Queensland Health
Chubb
UBS
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot